-1.98 | -1.41%
| Price and Volume | |
|---|---|
| Recent Price | 138.63 |
| 52 Week High | 152.31 |
| 52 Week Low | 94.58 |
| Avg. Daily Vol. (Mil) | 0.37 |
| Beta (3 year) | 0.96 |
| Share Related Items | |
| Mkt Cap (Mil) | 80,405.40 |
| Shares Out (Mil) | 580.00 |
| Float (Mil) | 0.00 |
| Dividend Information | |
| Yield % | 1.30 |
| Annual Dividend | 1.83 |
| Payout Ratio | 33.00 |
| Financial Strength | |
| Quick Ratio | 1.20 |
| Current Ratio | 1.70 |
| LT Debt/ Equity | 0.02 |
| Total Debt / Equity | 0.03 |
| Valuation Ratios | |
| Price Earnings | 25.00 |
| Price/Sales | 6.61 |
| Price/Book | 13.88 |
| Price/Cash Flow | 26.50 |
| Per Share Data | |
| Earnings | 5.56 |
| Sales | 20.97 |
| Book Value | 9.99 |
| Cash Flow | 5.22 |
| Business Summary | |
|---|---|
| Novo-Nordisk A/S is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products in Denmark and internationally. It has two business segments: Diabetes Care and Biopharmaceuticals. | |
| General Information | |
| Novo Alle
Bagsvaerd, 2880 |
|
| 1.0 | |
| www.novonordisk.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 32252 | |
| CEO: Mr. Lars Rebien Sorensen | |
| Short Interest | |
| Current Month (Mil) | 1.33 |
| Previous Month (Mil) | 1.30 |
| Short Interest Ratio (Days) | 4.00 |
| Management Effectiveness | |
| Return on Equity | 54.30 |
| Return on Assets | 28.70 |
| Return on Investments | 53.50 |
| Profitability | |
| Gross Margin | 80.20 |
| EBIT Margin | 34.80 |
| Profit Margin | 25.90 |
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note |
|
|---|---|---|---|---|
| 12,580.69 | 1,332.42 | 2,870.99 | 17.31 |
Oil *
106.79
|
|
UP
125.86 |
UP
14.60 |
UP
33.46 |
DOWN
0.14 |
10 Yr
1.73%
SPDR Gold
151.02
|
|
+1.01%
|
+1.11%
|
+1.18%
|
-0.80%
|
Data delayed 20 minutes |
Connect with TheStreet